REGRESSION OF LEFT-VENTRICULAR HYPERTROPHY AFTER MOXONIDIN THERAPY

Moxonidin is a newly developed anti-hypertensive drug with high selectivity for the recently described imidazol receptor in the medulla oblongata. In the following study the anti-hypertensive effect and regression of left ventricular hypertrophy were evaluated in 20 hypertensive patients after 6 months of moxonidin therapy. Cardiac hypertrophy was quantified by magnetic resonance imaging. Measurements of left ventricular septum and cavity diameters were made. After 6 months of therapy there was a significant reduction in blood pressure. Septal thickness was reduced from a pre-treatment average of 22.5 mm to 19.1 mm post therapy with a high significance.